Irbesartan Unichem

Irbesartan, the active ingredient in Irbesartan Unichem, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure and protect kidney function in certain diabetic patients. GNH USA supplies Irbesartan Unichem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to lower blood pressure and reduce renal stress.

- Hypertension: helps achieve target blood pressure levels in adults. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes and proteinuria.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Hyperkalemia: elevated potassium levels in blood tests. - Increased serum creatinine: modest rise indicating altered kidney function.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure causing fainting. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: signs of liver damage such as jaundice. - Neutropenia: dangerously low white‑blood‑cell count.

Before starting Irbesartan, patients should be evaluated for renal function, electrolyte balance, and pregnancy status.

- Monitor blood pressure: adjust dose to maintain target levels. - Check renal function: periodic serum creatinine and eGFR assessments. - Assess serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. - Contraindicated in pregnancy: risk of fetal toxicity; discontinue if pregnancy is confirmed. - Use caution in hepatic impairment: dose may need adjustment. - Store at below 25°C: keep in original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: combined use can cause excessive potassium rise and renal impairment. - Potassium‑sparing diuretics: increase risk of hyperkalemia. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): can diminish antihypertensive effect and affect kidney function. - CYP2C9 inhibitors (e.g., fluconazole): may increase Irbesartan plasma levels. - CYP2C9 inducers (e.g., rifampin): may reduce drug exposure. - Other antihypertensives: additive blood‑pressure lowering effect, monitor for hypotension.